The rewiring of metabolism in cancer is thought to result from hyperactivation of signaling pathways that instruct cells to grow. Sebastian et al. show that loss of the tumor suppressor SIRT6 transforms cells by activating tumor metabolism. This occurs independently of mutations in canonical growth signaling pathways and reveals a tumorigenic role for cancer metabolism.
The metabolic requirements of cancer cells differ from those of normal cells. Whereas normal cells take up and utilize nutrients to maintain homeostasis, cancer cells reprogram metabolism to facilitate growth and survival. For years, it was thought that such metabolic reprogramming was a consequence of tumorigenesis, where mutations in growth factor signal transduction pathways activate cellular proliferation, and that alterations in metabolism follow to enable tumor growth. Given the interconnectedness of these two processes, it has been difficult to disentangle cause from effect. In this issue of Cell, Sebastian et al. (2012) describe a role for SIRT6 in tumor metabolism in which conditional deletion of SIRT6 activates an anabolic metabolism program that is sufficient to promote tumorigenesis independent of canonical transforming events.
Alterations in glucose and glutamine metabolism are now recognized as common features in cancer, and numerous studies have mapped the signaling and genetic events that enable these phenomena. In general, the metabolic enzymes that drive anabolic metabolism are turned on downstream of growth factor signal transduction pathways ( Vander Heiden et al., 2009) . Such signaling converges on a common set of metabolic attributes that activate nutrient uptake and utilization in cell-building processes. Given that transcriptional programs that control cancer metabolism are activated as a consequence of unregulated growth signals, it has been difficult to ascertain the sequence of events in tumorigenesis and to determine the relative contribution of metabolic reprogramming to tumorigenesis. Very recently, several notable examples have demonstrated a causal role for activating metabolic adaptations in tumorigenesis. Among these are the genomic amplification of PHGDH, the rate-limiting enzyme in serine biosynthesis (Locasale et al., 2011; Possemato et al., 2011) , and overexpression of the glycine metabolizing enzyme GLDC . Although both of these enzymes concern serine/glycine metabolism, the work from these studies has demonstrated proof of principle that metabolic enzymes can function in an oncogenic role.
SIRT6 is a member of the sirtuin family of NAD( + )-dependent deacetylases that acts to maintain genomic stability and to repress gene transcription (Mostoslavsky et al., 2006) . Among the genes that SIRT6 represses are a number of enzymes involved in the homeostatic control of glucose metabolism (Zhong et al., 2010) . Consistent with this concept, Sebastian et al. (2012) (Gordan et al., 2007) . Similarly, loss of the transcriptional corepressor SIRT6 enables the direct upregulation of select HIF-1a target genes involved in glucose metabolism (such as Glut1, Pfk1, Pdk1, and Ldha). Importantly, HIF-1a is not activated directly, nor are other pathways with more pleiotropic effects on cellular proliferation and survival. As such, Sebastian et al. (2012) are able to decouple the effects of activating aerobic glycolysis on tumorigenesis from the more widespread effects that occur downstream of activated growth signaling pathways or HIF-1a overexpression. Indeed, the activation of aerobic glycolysis incurred upon deletion of SIRT6 promotes tumorigenesis in mouse models of colon cancer. Moreover, Sebastian et al. (2012) demonstrate that inhibition of aerobic glycolysis by short hairpin RNA (shRNA)-mediated knockdown of PDK1 or its pharmacological inhibition impairs SIRT6 loss-dependent tumorigenesis and tumor growth. Collectively, these results support the idea that the reprogramming of cancer metabolism is not merely a consequence of transformation but that aerobic glycolysis can promote transformation. Like HIF-1a, MYC expression is also frequently activated in cancer downstream of common growth factor signal transducing pathways, and MYC acts to drive anabolic metabolism (Gordan et al., 2007) . The metabolic output of MYC activation is highly tissue-and oncogene-context dependent. For example, MYC can activate pathways involved in anabolic glucose (Ying et al., 2012) or glutamine metabolism (Wise et al., 2008) . Sebastian et al. (2012) find that loss of SIRT6 also leads to the activation of a distinct subset of the MYC-dependent genes involved in ribosomal biogenesis and glutamine metabolism. Strikingly, this again does not occur downstream of growth factor signaling pathway activation but rather occurs as a result of loss of the corepressor function of SIRT6. Thus, the consequence of SIRT6 deletion is not an increase in HIF-1a or MYC levels, but rather an enhancement in the ability of these transcription factors to drive expression of specific target genes. Moreover, knockdown of MYC in the context of SIRT6 deletion dramatically impairs tumorigenesis and tumor growth. Collectively, this study demonstrates that loss of SIRT6 corepressor activity directly engages aerobic glycolysis, ribosomal biogenesis, and anabolic glutamine metabolism independent of mutations in growth factor signaling pathways. Activation of each of these distinct metabolic components is necessary for tumorigenesis, and together, this metabolic reprogramming is sufficient to transform cells (Figure 1) .
Although this body of work provides convincing evidence for a tumorigenic role of metabolic reprogramming, it also raises several fascinating questions. The first concerns the role of NAD + /NADH redox balance. The metabolic activity of SIRT6 requires the cofactor NAD + . Glycolysis drives the consumption of NAD + by GAPDH and may thereby impair SIRT6 activity due to limiting substrate. Thus, the activation of glycolysis may function in a manner parallel to SIRT6 loss by impairing SIRT6 activity, driving aerobic glycolysis in a feed-forward fashion. In addition, SIRT6 plays a role in maintaining genome stability (Mostoslavsky et al., 2006) . Although Sebastian et al. (2012) show that SIRT6 overexpression can revert the tumorigenic phenotype of SIRT6 deletion (to argue that irreversible genomic mutations are not a contributing factor), it is unclear whether SIRT6 overexpression affects cell transformation in the same fashion as SIRT6 deletion. It will be interesting to see how these phenomena influence the tumorigenic role of SIRT6 and the rewiring of cancer metabolism. (B) SIRT6 inhibits aerobic glycolysis, anabolic glutamine metabolism, and ribosome biogenesis. Together, activation of these metabolic pathways promotes tumorigenesis and tumor growth. Inhibition of aerobic glycolysis by knockdown of PDK1 using short hairpin RNA (shPDK1) or pharmacological inhibition with dichloroacetate (DCA) blocks the tumorigenic activity of SIRT6 loss.
